Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of TEV-48125 in Healthy Japanese and Caucasian Subjects
NCT02673567Phase 1Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2016
- Primary completion
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fremanezumab in migraine (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Maximum observed plasma drug concentration at 33 weeks, Time to maximum observed plasma drug concentration at 33 weeks and 4 more. Started Mar 2016; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02673567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02673567.